Table 1

Summary of the outcomes according to the three different referral centres therapeutic approaches

EAC 1EAC 2EAC 3p Value 1 vs 2p Value 1 vs 3p Value 2 vs 3
Sex, female78.8%68.6%74.5%
Age, years53.8±13.554.2±8.857.3±
Disease duration (months)5.8±3.47.7±2.55.5±7.0<0.0010.001<0.001
VERA (≤12 weeks)32.6%1%49.6%<0.0010.01<0.001
RF, % positive67.8%35.7%51.2%<0.0010.0020.01
Anti-CCP, % positive68.6%26.7%38.2%<0.001<0.0010.1
DAS28 T05.4±1.35.8±0.75.0±1.1<0.0010.008<0.001
DAS28 T122.8±1.34.0±1.33.0±1.1<0.0010.03<0.001
HAQ T01.2±0.71.1±0.41.2±
HAQ T120.4±0.50.7±0.40.4±0.6<0.0010.6<0.001
DMARD only T12 (% of patients)78.5%58.6%98.6%0.006<0.01<0.001
Anti-TNF therapy T12 (% of patients)31.5%41.4%1.4%0.14<0.001<0.001
DAS28 remission T12 (% of patients)49%19.5%36.6%<0.0010.090.006
ACR remission T12 (% of patients)20.6%13.3%8.5%
  • It can be seen that the approach was substantially different in the three early arthritis clinics.

  • ACR, American College of Rheumatology; CCP, cyclic citrullinated protein; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; EAC, early arthritis clinic; HAQ, health assessment questionnaire; RF, rheumatoid factor; TNF, tumour necrosis factor; T0, baseline; T12, 12-month follow-up; VERA, very early rheumatoid arthritis.